GlassScriptPhysician profile
Kriti Mehra
NPI 1487264933
$3,317.56
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $115 · 2021: $747 · 2022: $745 · 2023: $1,148 · 2024: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.26 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $391.95 | 2020-2024 | Farxiga, Lokelma, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $374.35 | 2021-2023 | Opdivo, Camzyos |
| Alexion Pharmaceuticals, INC. | $336.20 | 2021-2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $304.68 | 2020-2023 | Xarelto |
| Gilead Sciences, INC. | $294.88 | 2021-2024 | Veklury |
| Bayer Healthcare Pharmaceuticals INC. | $276.42 | 2022-2024 | |
| Pfizer INC. | $174.10 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.77 | 2021-2024 | Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.08 | 2020-2022 | |
| Fresenius Kabi USA, LLC | $66.79 | 2023-2024 | Idacio |
| Novo Nordisk INC | $64.28 | 2023 | Ozempic |
| Grifols USA, LLC | $54.69 | 2024 | Gamunex-C |
| Alnylam Pharmaceuticals INC. | $40.42 | 2024 | Onpattro |
| Incyte Corporation | $37.21 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $31.91 | 2022 | |
| Argenx US, INC. | $30.55 | 2024 | Vyvgart Hytrulo |
| Glaxosmithkline, LLC. | $29.04 | 2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $28.83 | 2024 | Jynarque |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.38 | 2022 | |
| Alcresta Therapeutics, INC. | $19.09 | 2023 | Relizorb |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kriti Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.